Content of Granule Marker Proteins
| Assay . | C Day 0 . | P Day 0 . | C Day 4 . | P Day 4 . |
|---|---|---|---|---|
| Lactoferrin (μg/mg protein) | 46.4 ± 6.8 | 65.4 ± 0.7 | 60.4 ± 8.7 | 23.3 ± 3.34-150 |
| Alkaline phosphatase (OD/min/mg protein) | 0.2 ± 0.0 | 0.4 ± 0.1 | 0.3 ± 0.1 | 4.5 ± 1.04-151 |
| Myeloperoxidase (OD/min/mg protein) | 4.0 ± 0.6 | 5.6 ± 0.3 | 5.8 ± 0.6 | 5.3 ± 0.6 |
| Lysozyme (OD/min/mg protein) | 0.9 ± 0.1 | 1.0 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 |
| Assay . | C Day 0 . | P Day 0 . | C Day 4 . | P Day 4 . |
|---|---|---|---|---|
| Lactoferrin (μg/mg protein) | 46.4 ± 6.8 | 65.4 ± 0.7 | 60.4 ± 8.7 | 23.3 ± 3.34-150 |
| Alkaline phosphatase (OD/min/mg protein) | 0.2 ± 0.0 | 0.4 ± 0.1 | 0.3 ± 0.1 | 4.5 ± 1.04-151 |
| Myeloperoxidase (OD/min/mg protein) | 4.0 ± 0.6 | 5.6 ± 0.3 | 5.8 ± 0.6 | 5.3 ± 0.6 |
| Lysozyme (OD/min/mg protein) | 0.9 ± 0.1 | 1.0 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 |
Total protein and granule marker proteins were measured as described in Materials and Methods.
Lactoferrin content was reduced after 5 days of G-CSF therapy compared with pretreatment levels (P = .0002). There was an increased amount of alkaline phosphatase after 5 days of G-CSF therapy (P = .0009). No alteration in the content of myeloperoxidase or lysozyme was recognized with G-CSF therapy. Neutrophil whole cell protein, in treated volunteers, was 1.8 ± 0.1 on day 0 and 1.7 ± 0.1 on day 4 (mg/mL). Results are expressed as mean ± SEM, n = 13 (matched pairs).
P = .0002.